Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01605799 · ClinicalTrials.gov registry record · Phase 2
IOK Treatment Study
A Phase 2 study of Post Traumatic Stress Disorder, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01605799: Completed Phase 2 study of Post Traumatic Stress Disorder, sponsored by VA Office of Research and Development.
NCT01605799 is a Phase 2 study of Post Traumatic Stress Disorder that has completed, run by VA Office of Research and Development. The registered enrollment target is 33 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01605799, a Phase 2 study of Post Traumatic Stress Disorder, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of this project are * 1\) to evaluate the effectiveness of a CBT treatment module addressing the mental health and functional impact of killing in the war zone, * 2\) to gather data on Veteran stakeholders' perceptions of acceptability and feasibility of the CBT treatment module, which would be used to further refine the intervention, and * 3\) to gather data on clinician stakeholders' perceptions of acceptability and feasibility of the CBT treatment module, which would be used to ensure that the module could be easily integrated into EBT for PTSD.
Primary Outcome
The PCL is a 17 item self-report measure of the 17 symptoms of PTSD per the DSM IV. Possible scores range from 17 (better outcome) to 85 (worse outcome).
Conditions Studied
Interventions
- BEHAVIORAL IOK Killing Treatment
- BEHAVIORAL Wait list control group
Study Locations (1)
California
- San Francisco VA Medical Center, San Francisco, CA - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT01605799 record still lists
NCT01605799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which IOK Killing Treatment is the first listed.
NCT01605799 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01605799 about?
NCT01605799 is a clinical study titled "IOK Treatment Study". The goals of this project are * 1\) to evaluate the effectiveness of a CBT treatment module addressing the mental health and functional impact of killing in the war zone, * 2\) to gather data on Veteran stakeholders' perceptions of acceptability and feasibility of the CBT treatment module, which wo...
What is the current status of trial NCT01605799?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2012-10. Estimated completion is 2015-01.
What conditions does trial NCT01605799 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT01605799?
The interventions under investigation include: IOK Killing Treatment (BEHAVIORAL), Wait list control group (BEHAVIORAL).
Who is sponsoring clinical trial NCT01605799?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01605799 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01605799's enrollment target sits among peer trials
33 204th of 262 higher than 58 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.
RECRUITING · Phase 2
-
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
RECRUITING · Phase 2
-
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
RECRUITING · Phase 2
-
MDMA for AUD/PTSD Comorbidity
RECRUITING · Phase 2
-
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia